<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03389490</url>
  </required_header>
  <id_info>
    <org_study_id>GLARGL08588</org_study_id>
    <nct_id>NCT03389490</nct_id>
  </id_info>
  <brief_title>Toujeo Versus NPH Self-titration Study</brief_title>
  <official_title>A Pilot Study to Describe the Glycaemic Variability of Insulin Glargine 300U/ml Versus NPH (Neutral Protamine Hagedorn) in the Insulin-naïve Type 2 Diabetes Patients Following a Patient-adjusted Insulin Algorithm in Hong Kong</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elaine Chow</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 24 week, multicentre, prospective, randomized, controlled, parallel-designed (1:1)&#xD;
      pilot study.The study will compare glycemic variability in patients treated with insulin&#xD;
      glargine U300/ml insulin versus conventional (NPH) insulin using a self titration&#xD;
      algorithm.50 type 2 diabetes patients who are newly started on insulin will be recruited.&#xD;
      They will be randomly allocated to either insulin glargine U300 or NPH insulin for 26 weeks.&#xD;
      All subjects will follow a insulin-self titration algorithm. The study will consist of 9&#xD;
      visits over 26 weeks. Blood glucose variability will be collected by CGM for 7 consecutive&#xD;
      days at baseline (week -1) and at week 24.Secondary endpoints other than data on glycemic&#xD;
      variability, including HbA1c, fasting plasma glucose, inflammatory markers will be measured&#xD;
      during three periods (week 0, week 12 and week 24).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">May 1, 2020</completion_date>
  <primary_completion_date type="Actual">December 17, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic variability</measure>
    <time_frame>24 weeks</time_frame>
    <description>Standard deviation of glucose from continuous glucose monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycemic variability</measure>
    <time_frame>24 weeks</time_frame>
    <description>Mean Amplitude of Glycemic excursions and Means of Daily Differences</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage time in target</measure>
    <time_frame>24 weeks</time_frame>
    <description>Percentage of time &lt;3.0mmol/L and &gt;10.0mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated haemoglobin</measure>
    <time_frame>24 weeks</time_frame>
    <description>HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting blood glucose</measure>
    <time_frame>24 weeks</time_frame>
    <description>FPG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypoglycemia</measure>
    <time_frame>24 weeks</time_frame>
    <description>Overall incidence of hypoglycemia and nocturnal hypoglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving HbA1c &lt;7.0%</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of patients achieving HbA1c &lt;7.0% at week 24 without confirmed hypoglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment satisfaction</measure>
    <time_frame>24 weeks</time_frame>
    <description>ITSQ questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>24 weeks</time_frame>
    <description>change in hs C reactive protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in heart rate variability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin glargine 300U/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neutral Protamine Hagedorn insulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine 300 UNT/ML</intervention_name>
    <description>Self titration of insulin glargine U300</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neutral protamine hagedorn insulin</intervention_name>
    <description>Self titration of NPH insulin</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetic suboptimally controlled on their previous antidiabetic treatment&#xD;
&#xD;
               -  18 ≤ age ≤ 75&#xD;
&#xD;
               -  Stable dose of oral antidiabetic treatment for &gt; 8 weeks&#xD;
&#xD;
               -  The number of OADs that the patients used should be &quot;3&quot; or less&#xD;
&#xD;
               -  HbA1c level &gt; 7.0% and &lt; 10%&#xD;
&#xD;
               -  Fasting plasma glucose &gt; 8mmol/L and &lt;15mmol&#xD;
&#xD;
               -  BMI &lt; 40 kg/m2&#xD;
&#xD;
               -  Patient who is capable and willing to perform regular SMBG&#xD;
&#xD;
               -  Patient who is capable and willing for insulin injection&#xD;
&#xD;
               -  Confirmed written consent&#xD;
&#xD;
               -  Insulin naïve&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in a clinical trial with any investigational drug used with curative&#xD;
             intent and within 30 days prior to study entry&#xD;
&#xD;
          -  Patient known to have hypoglycaemia unawareness or recurrent major hypoglycaemia&#xD;
&#xD;
          -  Any product containing prandial insulin&#xD;
&#xD;
          -  Concomitant medication known to interface with glucose metabolism (such as systematic&#xD;
             steroids)&#xD;
&#xD;
          -  Change in dose of non-insulin anti-diabetic treatment or initiation of new&#xD;
             anti-diabetic medications in the last 8 weeks prior to screening&#xD;
&#xD;
          -  Patients treated with steroid or nonsteroidal anti-inflammatory drugs&#xD;
&#xD;
          -  Patient who had experienced an acute concurrent illness during the 3-month period&#xD;
             before the investigation&#xD;
&#xD;
          -  Patient with hepatic disease and end-stage renal disease&#xD;
&#xD;
          -  Patients unable to comply with follow-up visits&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elaine Chow</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <state>Shatin</state>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 26, 2017</study_first_submitted>
  <study_first_submitted_qc>December 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2018</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Elaine Chow</investigator_full_name>
    <investigator_title>Dr, Clinical Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
    <mesh_term>Isophane Insulin, Human</mesh_term>
    <mesh_term>Isophane insulin, beef</mesh_term>
    <mesh_term>Protamines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

